Post by Glenmark Pharmaceuticals

We are pleased to announce that Glenmark Specialty S.A., our wholly owned subsidiary, will be advancing its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. To know more about this announcement, please visit: https://bit.ly/4fdi3zA